A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 216-225

  Hitt, R ^a   Grau, J J ^b   Lopez Pousa A ^c   Berrocal, A ^d   Garcia Giron C ^e   Irigoyen, A ^f   Sastre, J ^g   Martinez Trufero J ^h   Brandariz Castelo, J A ^a   Verger, E ^b   Cruz Hernandez J J ⁱ  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Chemoradiotherapy; Head and neck cancer; Induction chemotherapy; Unresectable

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER LOCALIZATION; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOKALEMIA; HYPONATREMIA; INFECTION; INOPERABLE CANCER; KIDNEY DISEASE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ODYNOPHAGIA; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT FAILURE; VEIN THROMBOSIS; VOMITING;

CHEMORADIOTHERAPY; HEAD AND NECK CANCER; INDUCTION CHEMOTHERAPY; UNRESECTABLE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; TAXOIDS;

EID: 84899476710     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt461     Document Type: Article

References (15)

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr (3 December 2011, date last accessed).
2. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-899.
3. Posner MR, Haddad RI, Wirth L et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004; 31: 778-785.
4. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-1154.
5. Pignon JP, Le MA, Maillard E et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92(1): 4-14.
6. Brockstein B, Haraf DJ, Rademaker AW et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15: 1179-1186.
7. Argiris A. Induction chemotherapy for head and neck cancer: will history repeat itself? J Natl Compr Canc Netw 2005; 3: 393-403.
8. Fu KK, Phillips TL, Silverberg IJ et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987; 5: 1410-1418.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
10. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
11. Vermorken JB, Remenar E, van HC et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
12. Paccagnella A, Mastromauro C, D'Amanzo P et al. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future? Oncologist 2010; (Suppl 3); 15: 8-12.
13. Paccagnella A, Ghi MG, Loreggian L et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010; 21: 1515-1522.
14. List MA, Stracks J, Colangelo L et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol 2000; 18: 877-884.
15. Goon PK, Stanley MA, Ebmeyer J et al. HPV & head and neck cancer: a descriptive update. Head Neck Oncol 2009; 1: 36.